Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for Lorlatinib

    Client Email Product

    Lorlatinib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Formulations

    GLOBAL SALES INFORMATION

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    6
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    6
    API REF. PRICE (USD / KG)
    25,172

    API Market Place

    0

    INTERMEDIATES

    0

    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    2
    Europe

    Europe

    0

    Canada

    Canada

    2
    Australia

    Australia

    2
    South Africa

    South Africa

    0

    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    64.00

    Annual Reports

    0

    FDF Market Place

    0

    EXCIPIENTS

    0

    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    10

    USFDA Exclusivities

    10
    DIGITAL CONTENT

    Blog #PharmaFlow

    0

    News

    30
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Pfizer and Strata expand clinical partnership for cancer trial
    Pfizer and Strata expand clinical partnership for cancer trial

    https://www.clinicaltrialsarena.com/news/pfizer-strata-partnership-cancer-trial/

    CLINICALTRIALSARENA
    14 Sep 2022
    Share Share
    Amber Specialty Added to Pfizer’s Limited Distribution Network
    Amber Specialty Added to Pfizer’s Limited Distribution Network

    https://www.businesswire.com/news/home/20220803005649/en

    BUSINESSWIRE
    03 Aug 2022
    Share Share
    Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC
    Pfizer’s Lorviqua OKed as 1st-line therapy for ALK-positive NSCLC

    http://www.koreabiomed.com/news/articleView.html?idxno=13724

    Kim Yun-mi KOREABIOMED
    19 May 2022
    Share Share
    EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC
    EC Approves LORVIQUA as First-Line Treatment for ALK-Positive NSCLC

    https://www.businesswire.com/news/home/20220128005304/en

    BUSINESSWIRE
    28 Jan 2022
    Share Share
    Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc
    Pfizer’s Lorbrena gets US FDA approval to treat ALK-positive nsclc

    http://www.pharmabiz.com/NewsDetails.aspx?aid=135923&sid=2

    PHARMABIZ
    04 Mar 2021
    Share Share
    Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval
    Pfizer’s ALK inhibitor Lorbrena scores expanded FDA approval

    http://www.pmlive.com/pharma_news/pfizers_alk_inhibitor_lorbrena_scores_expanded_fda_approval_for_first-line_nsclc_1364615

    Lucy Parsons PMLIVE
    04 Mar 2021
    Share Share
    Pfizer’s Lorbrena scores US priority review
    Pfizer’s Lorbrena scores US priority review

    http://www.pharmatimes.com/news/pfizers_lorbrena_scores_us_priority_review_1360683

    Lucy Parsons PHARMATIMES
    04 Jan 2021
    Share Share
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer

    https://www.businesswire.com/news/home/20201228005232/en/LORBRENA%C2%AE-lorlatinib-sNDA-in-Previously-Untreated-ALK-Positive-Lung-Cancer-Accepted-for-Priority-Review-by-U.S.-FDA

    BUSINESSWIRE
    28 Dec 2020
    Share Share
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer

    https://www.businesswire.com/news/home/20201228005232/en

    BUSINESSWIRE
    28 Dec 2020
    Share Share
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer

    https://www.businesswire.com/news/home/20201228005232/en/LORBRENA%C2%AE-lorlatinib-sNDA-in-Previously-Untreated-ALK-Positive-Lung-Cancer-Accepted-for-Priority-Review-by-U.S.-FDA

    BUSINESSWIRE
    28 Dec 2020
    Share Share
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer
    LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer

    https://www.businesswire.com/news/home/20201228005232/en

    BUSINESSWIRE
    28 Dec 2020
    Share Share
    CROWN TRIAL SUPPORTS LORLATINIB AS A FUTURE FIRST-LINE STANDARD TREATMENT
    CROWN TRIAL SUPPORTS LORLATINIB AS A FUTURE FIRST-LINE STANDARD TREATMENT

    https://www.esmo.org/meetings/esmo-virtual-congress-2020/daily-reporter/daily-reporter-news/crown-trial-supports-lorlatinib-as-a-future-first-line-standard-treatment-in-alk-positive-non-small-cell-lung-cancer

    ESMO
    21 Sep 2020
    Share Share
    ESMO: Pfizer's Lorbrena Makes Case To Claim ALK + Lung Cancer CROWN
    ESMO: Pfizer's Lorbrena Makes Case To Claim ALK + Lung Cancer CROWN

    https://scrip.pharmaintelligence.informa.com/SC142990/ESMO-Pfizers-Lorbrena-Makes-Case-To-Claim-ALK-Lung-Cancer-CROWN

    Kevin Grogan INFORMA
    20 Sep 2020
    Share Share
    Pfizer says Lorbrena met primary goal in lung cancer trial
    Pfizer says Lorbrena met primary goal in lung cancer trial

    https://www.clinicaltrialsarena.com/news/pfizer-lorbrena-crown-data/

    CLINICALTRIALSARENA
    06 Aug 2020
    Share Share
    Pfizer's Lorbrena bests Xalkori in PhIII readout — is it a potential successor?
    Pfizer's Lorbrena bests Xalkori in PhIII readout — is it a potential successor?

    https://endpts.com/pfizers-lorbrena-bests-xalkori-in-phiii-readout-is-it-a-potential-successor/

    Max Gelman ENDPTS
    06 Aug 2020
    Share Share
    Pfizer's Lorbrena makes play for earlier lung cancer use
    Pfizer's Lorbrena makes play for earlier lung cancer use

    https://www.fiercepharma.com/pharma/pfizer-s-lorbrena-makes-play-for-earlier-lung-cancer-use-xalkori-topping-data

    Carly Helfand FIERCE PHARMA
    05 Aug 2020
    Share Share
    LORBRENA® (LORLATINIB) SIGNIFICANTLY IMPROVES PROGRESSION-FREE
    LORBRENA® (LORLATINIB) SIGNIFICANTLY IMPROVES PROGRESSION-FREE

    https://www.pfizer.com/news/press-release/press-release-detail/lorbrenar-lorlatinib-significantly-improves-progression#:~:text=(NYSE%3APFE)%20today%20announced,(PFS)%2C%20as%20compared%20to

    PRESS RELEASE
    05 Aug 2020
    Share Share
    LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival
    LORBRENA® (lorlatinib) Significantly Improves Progression-Free Survival

    https://www.businesswire.com/news/home/20200805005244/en

    BUSINESSWIRE
    04 Aug 2020
    Share Share
    NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance
    NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance

    http://www.pmlive.com/pharma_news/nice_backs_roches_gazyvaro,_pfizers_lorviqua_in_new_guidance_1340211

    Phil Taylor PMLIVE
    13 May 2020
    Share Share
    Pfizer to present clinical trials of 18 approved & investigational medicines
    Pfizer to present clinical trials of 18 approved & investigational medicines

    http://www.pharmabiz.com/NewsDetails.aspx?aid=124113&sid=2

    PHARMABIZ PHARMABIZ
    13 May 2020
    Share Share
    NICE final guidance backs Pfizer's Lorviqua
    NICE final guidance backs Pfizer's Lorviqua

    http://www.pharmatimes.com/news/nice_final_guidance_backs_pfizers_lorviqua_1340196

    Selina McKee PHARMA TIMES
    13 May 2020
    Share Share
    New Breakthrough Treatment for Patients with ALK-Positive Lung Cancer
    New Breakthrough Treatment for Patients with ALK-Positive Lung Cancer

    https://www.biospectrumasia.com/news/25/14970/new-breakthrough-treatment-for-patients-with-alk-positive-lung-cancer.html

    BIOSPECTRUM ASIA
    27 Nov 2019
    Share Share
    Inivata collaborates with EORTC
    Inivata collaborates with EORTC

    https://www.globenewswire.com/news-release/2019/10/29/1936873/0/en/Inivata-and-the-European-Organisation-for-Research-and-Treatment-of-Cancer-EORTC-collaborate-in-Phase-II-NSCLC-study.html

    GLOBENEWSWIRE
    29 Oct 2019
    Share Share
    Roche fields first approval for Rozlytrek
    Roche fields first approval for Rozlytrek

    https://endpts.com/roche-fields-first-approval-for-rozlytrek-in-the-run-up-to-a-showdown-with-eli-lilly-pfizer/

    Amber Tong ENDPTS
    19 Jun 2019
    Share Share
    Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal
    Pfizer, ‘never say never’ with big M&A, inks $11.4B Array cancer deal

    https://www.fiercepharma.com/pharma/pfizer-never-say-never-m-a-buys-oncology-innovator-array-for-11-4b

    Angus Liu FIERCE PHARMA
    18 Jun 2019
    Share Share
    Pfizer scores conditional EU approval in ALK-positive lung cancer with Lorviqua
    Pfizer scores conditional EU approval in ALK-positive lung cancer with Lorviqua

    http://www.pharmafile.com/news/521969/pfizer-scores-conditional-european-approval-alk-positive-lung-cancer-lorviqua

    PHARMAFILE
    08 May 2019
    Share Share
    Committee for medicinal products for human use (CHMP)
    Committee for medicinal products for human use (CHMP)

    https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-28-31-january-2019_en.pdf

    EMA
    28 Jan 2019
    Share Share
    Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
    Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?

    https://endpts.com/pfizer-racks-up-its-third-cancer-drug-ok-in-2-months-but-is-it-enough-to-replace-regular-price-hikes/

    John Carroll ENDPTS
    02 Nov 2018
    Share Share
    U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
    U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC

    https://www.businesswire.com/news/home/20181102005583/en

    BUSINESSWIRE
    02 Nov 2018
    Share Share
    Pfizer’s lorlatinib clears first hurdle to UK early access scheme
    Pfizer’s lorlatinib clears first hurdle to UK early access scheme

    http://www.pharmatimes.com/news/pfizers_lorlatinib_clears_first_hurdle_to_uk_early_access_scheme_1249701

    Selina McKee PHARMA TIMES
    22 Aug 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search